Who imagined the industry could develop several COVID-19 vaccines and roll them out to millions in a matter of months? Manufacturers are rightly receiving a lot of credit, which Barry Silverstein thinks provides a rare opportunity to rebrand. But regulators have played a key role too – working at breakneck speed without cutting any corners in terms of safety. Here, the EMA explains how they did it. Elsewhere, we have a breakthrough in cold tumor drug discovery and a new project to get macromolecules across the intestinal epithelial barrier.
All the best, James Strachan, Deputy Editor
|